SG47043A1 - Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides - Google Patents

Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides

Info

Publication number
SG47043A1
SG47043A1 SG1996004005A SG1996004005A SG47043A1 SG 47043 A1 SG47043 A1 SG 47043A1 SG 1996004005 A SG1996004005 A SG 1996004005A SG 1996004005 A SG1996004005 A SG 1996004005A SG 47043 A1 SG47043 A1 SG 47043A1
Authority
SG
Singapore
Prior art keywords
biodegradeble
polyesters
molecular conjugates
bioactive polypeptides
ionic molecular
Prior art date
Application number
SG1996004005A
Other languages
English (en)
Inventor
Shalaby SHALABY
Steven A Jackson
Jacques-Pierre Moreau
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of SG47043A1 publication Critical patent/SG47043A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicinal Preparation (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG1996004005A 1993-01-06 1994-01-05 Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides SG47043A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE930005 1993-01-06
CNB941085236A CN1163260C (zh) 1993-01-06 1994-07-20 可生物降解聚酯和生物活性多肽的离子性分子轭合物

Publications (1)

Publication Number Publication Date
SG47043A1 true SG47043A1 (en) 1998-03-20

Family

ID=37075859

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004005A SG47043A1 (en) 1993-01-06 1994-01-05 Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides

Country Status (20)

Country Link
EP (1) EP0678018B1 (ja)
JP (1) JPH08505395A (ja)
CN (1) CN1163260C (ja)
AT (1) ATE236655T1 (ja)
AU (1) AU680650B2 (ja)
CA (1) CA2150574A1 (ja)
CZ (2) CZ293425B6 (ja)
DE (1) DE69432459T2 (ja)
DK (1) DK0678018T3 (ja)
ES (1) ES2196023T3 (ja)
FI (1) FI114898B (ja)
HU (1) HU220137B (ja)
NZ (1) NZ261250A (ja)
PL (1) PL174772B1 (ja)
PT (1) PT678018E (ja)
RU (2) RU2185393C2 (ja)
SG (1) SG47043A1 (ja)
SK (1) SK74495A3 (ja)
WO (1) WO1994015587A2 (ja)
ZA (1) ZA9477B (ja)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
RU2165942C2 (ru) * 1996-04-23 2001-04-27 Кинертон Лимитид Биоразрушаемый сложный полиэфир и способ его получения (варианты)
AU750739B2 (en) * 1996-04-23 2002-07-25 Ipsen Manufacturing Ireland Limited Methods for preparing biodegradable polyesters and derivatives thereof
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU779930B2 (en) * 1996-12-11 2005-02-17 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DK1204429T3 (da) * 1999-08-18 2004-03-08 Sod Conseils Rech Applic Præparat til forsinket frigivelse af et peptid
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
AU2001251157A1 (en) 2000-03-31 2001-10-15 Paratek Pharmaceuticals, Inc 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
EP1383376A4 (en) * 2001-03-19 2006-03-08 Praecis Pharm Inc PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
PT2218448E (pt) 2002-12-13 2016-01-26 Durect Corp Sistema oral de entrega de fármaco que compreende materiais transportadores líquidos de alta viscosidade
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
BR0316685A (pt) 2002-12-17 2005-11-01 Nastech Pharm Co Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
CN101787073B (zh) 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 治疗胃肠病的方法和组合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1822851B (zh) 2003-05-15 2011-04-13 塔夫茨大学信托人 肽和多肽药物的稳定类似物
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
RS52198B (en) 2004-09-17 2012-10-31 Durect Corporation LOCAL ANESTHETIC SOLUTION CONTAINING SAIB SUSTAINABLE ACTION
US20090054320A1 (en) 2005-04-20 2009-02-26 Protemix Discovery Limited Vesiculins
WO2006125119A1 (en) 2005-05-17 2006-11-23 Sarcode Corporation Compositions and methods for treatment of eye disorders
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
BRPI0615573A2 (pt) 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
US7932231B2 (en) 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2707815T3 (es) 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
CA2706931C (en) 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010077422A2 (en) 2008-10-29 2010-07-08 Wyeth Llc Formulations of single domain antigen binding molecules
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
KR101224004B1 (ko) * 2009-12-29 2013-01-22 주식회사 삼양바이오팜 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법
CN103119062A (zh) 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
CN103080185B (zh) * 2010-08-31 2015-07-01 巴斯夫欧洲公司 基于柠檬酸的支化聚酯、其制备及应用
BRPI1003424A2 (pt) * 2010-09-08 2013-01-08 Univ Rio De Janeiro sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
NZ705124A (en) 2010-10-01 2016-08-26 Biogen Ma Inc Interferon-beta for use as monotherapy or in combination with other cancer therapies
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
RU2662818C2 (ru) * 2011-07-22 2018-07-31 Иннокор Текнолоджис Б.В. Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений
EP4406950A2 (en) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197938A1 (en) 2013-06-13 2014-12-18 Antisense Therapeutics Ltd Combination therapy
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US9181427B2 (en) * 2013-12-11 2015-11-10 Ethicon, Inc. Absorbable bimodal polymeric blend compositions, processing methods, and medical devices
JP6707537B2 (ja) * 2014-11-14 2020-06-10 レーム・ゲーエムベーハーＲｏｅｈｍ ＧｍｂＨ 粒子の形の生体吸収性ポリエステルの製造方法
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
TR201702016A2 (tr) 2017-02-10 2018-08-27 Tuerkiye Bilimsel Ve Teknolojik Arastirma Kurumu Tuebitak Düşük mali̇yetli̇ yüksek moleküler ağirlikli ve yüksek çözünürlüğe sahi̇p poli̇gli̇koli̇k asi̇t sentezi̇
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation REDUCED IMPURITY EXTENDED-RELEASE DRUG DELIVERY SYSTEMS AND METHODS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
US5071909A (en) * 1989-07-26 1991-12-10 Millipore Corporation Immobilization of proteins and peptides on insoluble supports
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same

Also Published As

Publication number Publication date
CN1115252A (zh) 1996-01-24
WO1994015587A2 (en) 1994-07-21
FI114898B (fi) 2005-01-31
CZ173495A3 (en) 1996-01-17
JPH08505395A (ja) 1996-06-11
HUT73188A (en) 1996-06-28
RU2185393C2 (ru) 2002-07-20
EP0678018A1 (en) 1995-10-25
HU9502029D0 (en) 1995-09-28
NZ261250A (en) 1997-08-22
SK74495A3 (en) 1997-01-08
ZA9477B (en) 1994-08-11
FI953314A0 (fi) 1995-07-05
EP0678018B1 (en) 2003-04-09
CN1163260C (zh) 2004-08-25
DK0678018T3 (da) 2003-04-28
WO1994015587A3 (en) 1994-09-01
ES2196023T3 (es) 2003-12-16
EP0678018A4 (en) 1998-09-09
CA2150574A1 (en) 1994-07-21
PL174772B1 (pl) 1998-09-30
AU5992194A (en) 1994-08-15
PT678018E (pt) 2003-08-29
DE69432459T2 (de) 2003-11-27
CZ293378B6 (cs) 2004-04-14
CZ293425B6 (cs) 2004-04-14
FI953314A (fi) 1995-07-05
AU680650B2 (en) 1997-08-07
RU2146128C1 (ru) 2000-03-10
ATE236655T1 (de) 2003-04-15
PL309776A1 (en) 1995-11-13
DE69432459D1 (de) 2003-05-15
HU220137B (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
SG47043A1 (en) Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides
CA2358829A1 (en) Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
AU1258997A (en) Novel dicarboxylic acids and anhydrides, their preparation and use
NZ503007A (en) Conjugates that contain the homeodomain of antennapedia
GR3019098T3 (en) Pressurised aerosol compositions.
PL323735A1 (en) Ionic molecular conjugates of n-acylated derivatives of poly92-amino-2-dezoxy-d-glucose) and polypeptides
FR2471394B1 (ja)
EP0634999A4 (en) Novel amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels.
AU7559691A (en) 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
AU2415599A (en) Rantes mutants and therapeutic applications thereof
CA2247998A1 (en) Fragments of cr1 and their use
AU8214091A (en) Methods to make and use proteinaceous material present in kinin-free high molecular weight kininogen
Matthews When to white box test
IL175808A0 (en) Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
Greenfield et al. Toxin conjugates.
CA2153071A1 (en) Derivatized calcitonins
DZ1696A1 (fr) Substitution d'un électolyte syanuré toxique et polluant par des électrolytes moins toxiques dans lesustème cu-ni-cr.